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Background: We summarize our experience of the diagnosis, surgical treatment, and prognosis of solid
pseudopapillary tumors (SPTs).
Methods: We carried out a retrospective study of clinical data from a series of 17 patients with SPT managed in
two hospitals between October 2001 and November 2011.
Results: All of the 17 patients were female and the average age at diagnosis was 26.6 years (range 11 years to 55 years).
The tumor was located in the body or tail in ten patients, the head in five patients, and the neck in two patients. The
median tumor size was 5.5 cm (range 2 cm to 10 cm). All 17 patients had curative resections, including seven distal
pancreatectomies, five local resections, four pancreaticoduodenectomies, and one central pancreatectomy. Two patients
required concomitant splenic vein resection due to local tumor invasion. All patients were alive and disease-free at a
median follow-up of 48.2 months (range 2 to 90 months). There were no significant associations between
clinicopathologic factors and malignant potential of SPT. Ki-67 was detected in three patients with pancreatic
parenchyma invasion.
Conclusions: The SPT is an infrequent tumor, typically affecting young women without notable symptoms. Surgical
resection is justified even in the presence of local invasion or metastases, as patients demonstrate excellent long-term
survival. Positive immunoreactivity for Ki-67 may predict the malignant potential of SPTs.Background
The solid pseudopapillary tumor (SPT) of the pancreas
was first reported by Frantz in 1959 [1]. It is a rare
neoplasm of low malignant potential, and accounts for
approximately 1% of pancreatic tumors [2]. This tumor
primarily affects young women and is usually treated
with surgical resection [3]. After resection and follow-
up, there is generally a relatively favorable prognosis.
Recently, the number of cases reported in the literature
has been steadily rising; however, the pathogenesis and
guidelines for SPT treatment remain unclear. In this
study, we report our clinical experience with 17 cases
of SPTs.* Correspondence: yupengfei23@163.com
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Between October 2001 and November 2011, 17 patients
who underwent surgery for a pathologically confirmed
SPT at the Department of Abdominal Surgery, Zhejiang
Cancer Hospital and the Department of Surgery, Second
Affiliated Hospital of JiaXing Medical College were
reviewed retrospectively. Patients’ clinical presentation,
radiological details, surgical data, pathological features,
postoperative course, and long-term survival were col-
lected and analyzed. Outpatient records combined with
telephone interviews were used for follow-up.
Pathologically, SPT was defined as malignant if it
demonstrated extrapancreatic invasion, distant metastases,
pancreatic parenchymal invasion, or perineural or vascular
invasion [4]. Univariate analyses of predictive features of
malignancy were performed to compare clinicopathologic
factors. All statistical analyses were performed with the
computer program Statistical Package for Social Sciences
(SPSS) 16.0 for Windows (Chicago, Illinois).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Patient characteristics
All of the 17 patients were women, aged from 11 to 55
years (mean 26.6 years). The clinical presentation is unspe-
cific, including abdominal pain (35.3%), abdominal discom-
fort (27.3%), abdominal distension (27.3%), back pain
(11.8%), and vomiting (9.1%). Three patients whose SPT
was found during routine physical examinations were
asymptomatic. The patients had a median symptom dur-
ation of one month (range 5 days to 11 months). The
tumors were 5.5 cm in diameter, on average (range 2 cm to
10 cm), and were located in the body or tail in ten patients,
the head in five patients, and the neck in two patients. The










Abdominal pain 6 35.3%
Abdominal discomfort 4 27.3%
Abdominal distension 4 27.3%
Back pain 2 11.8%
Vomiting 1 5.9%
Asymptomatic 3 17.6%
Size (cm, mean (range)) 5.5 (2-10)
Location
Body or tail 10 58.8%Preoperative examination and diagnosis
Radiological investigations were performed before oper-
ation, including computed tomography (CT) in twelve
patients, ultrasonography (US) in eight patients, mag-
netic resonance imaging (MRI) in four patients, and
US-guided fine needle aspiration cytology (FNAC) in
two patients. Figures 1 and 2 show CT and US images
of the SPT. The mass was described on cross-sectional
imaging as heterogenous (solid and cystic) in ten
patients and solid in seven patients. Calcifications were
present in 4 of the 17 patients, while hemorrhage or ne-
crosis was detected in 6 patients.
None of the patients had a definitive preoperative diagno-
sis and a correct diagnosis was made in six patients. Mis-
diagnoses included pancreatic adenocarcinoma (n = 6),
cystadenomas (n = 3), islet cell tumors (n = 1), and pancre-
atic cyst (n = 1).Head 5 29.4%
Neck 2 11.8%
Tumor feature
Solid and cystic 10 58.8%
Solid 7 41.2%
Surgical treatment
Distal pancreatectomy 2 11.8%
Distal pancreatectomy + splenectomy 5 29.4%
Local resection 3 17.6%
Local resection + splenic vein 2 11.8%
Resection
Whipple 4 23.5%
Central pancreatectomy 1 5.9%
Follow-up (months, mean (range)) 48.2 (2-90)
Outcome
Alive 17 100%
Dead 0 0%Surgical data
All 17 patients underwent surgical exploration. Seven
patients with lesions in the pancreas body or tail
underwent a distal pancreatectomy, including two
spleen-preserving resections. Five patients underwent
local resection and two of them had concomitant
splenic vein resection due to local tumor invasion. The
remaining five patients underwent pancreaticoduode-
nectomy (Whipple, four cases) and central pancreatec-
tomy (one case). Total surgery time ranged from 1.5 to
6.5 hours (mean 3.7 hours). Blood transfusion was
needed in five patients during surgery; each patient
received 2 units of blood.
All 17 patients had R0 resections and there were no sur-
gical mortalities. Postsurgical complications occurred in
five patients. One patient had pulmonary infection four
days after surgery. Another patient had been found to have
a pseudocyst in the first follow-up. Three patients hadpancreatic leakage. The median postsurgical stay was 10.3
days (range 7 to 17 days).Pathological features
Grossly, the tumor is well encapsulated and is usually well
demarcated from the pancreas. The cut surface shows
large spongy areas of hemorrhage alternating with both
solid and cystic degeneration. The tumors contain a mix-
ture of solid, cystic, and pseudopapillary patterns in vari-
ous proportions. Four patients had a malignant SPT; two
patients had splenic vein infiltration and the other two had
Figure 1 Contrast-enhanced CT shows a solid and cystic mass
with a calcification (arrowed) located in the tail of
the pancreas.
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No patients had lymph node metastasis.
Immunohistochemical studies were performed in all 17
cases. Results were typically positive for vimentin, α1-
antitrypsin, and neuron-specific enolase. Progesterone
receptors, but usually not estrogen receptors, were
variably present. Synaptophysin, cytokeratin, and chro-
mogranin A were expressed only focally in a few
tumors. Ki-67 was detected in three patients with pan-
creatic parenchyma invasion. Figure 3 shows the histo-
pathologic image results.Follow-up
Follow-up included clinical examination, routine la-
boratory tests, abdominal US, and CT or MRI every 3
months. The patients were followed up for a mean dur-
ation of 48.2 months, (range 2 to 90 months) and all 17
patients were alive with no evidence of disease recur-
rence or metastasis.Predictive factors of malignancy
On univariate analysis, none of the features, including
age, tumor size, tumor location, increased tumor mar-
kers, and tumor characteristics, was predictive of malig-
nant SPTs (Table 2).Figure 2 US of the left upper quadrant shows a large lesion
located in the body and tail of the pancreas.Discussion
Solid pseudopapillary tumor of the pancreas is a rare
neoplasm with a low malignant potential, usually affect-
ing young women in the second or third decade of life.The pathogenesis of the tumor is unknown, although its
tendency to affect young women has suggested that sex
hormones may be involved in the origin of SPT. How-
ever, no differences in immunohistochemical stains for
sex hormone-receptor proteins or in clinicopathologic
characteristics had been found attributable to sex alone
[5]. Sun et al. [6] reported that 62.5% of SPT patients
had been infected by Hepatitis B virus (HBV), which
may be involved in the pathogenesis of SPTs. However,
this association has not been confirmed by other
researchers.
The clinical presentation of SPTs is usually unspecific
and two or more symptoms usually coexist. Most of
the patients presented with unclear clinical features, in-
cluding abdominal pain, abdominal discomfort, poor
appetite, and nausea, which are related to tumor com-
pression of the adjacent organs. Because patients lack
distinctive symptoms, the majority of these tumors are
diagnosed during complementary imaging investiga-
tions, such as CT or US of the abdomen. On US or CT,
the lesion is usually seen to be large, and its internal struc-
ture ranges from cystic thick-walled or with an inner
irregular margin to a predominantly solid mass with some
cystic component [7]. On dynamic contrast-enhanced
CT, the tumor is enhanced less than the adjacent nor-
mal pancreas [8]. Magnetic resonance imaging is better
than CT in differentiating the cystic or solid component
inside the tumor and providing information about
resectability. The use of FNAC, either percutaneously
or endoscopic ultrasound guided, can help distinguish
SPTs from other pancreatic tumors. However, seeding
of the needle tract by neoplastic cells and such compli-
cations as bleeding, pancreatic fistula, and biliary
fistula during the procedure have also been reported [9].
Figure 3 Histopathology of SPTs. (A) Sheets and cords of cells arranged around fibrovascular septa and pseudopapillary structures are formed.
(H&E × 100). (B) Immunohistochemical staining for α1-antitrypsin (original magnification × 400). (C) Immunohistochemical staining for vimentin
(original magnification × 400). (D) Immunohistochemical staining for neuron-specific enolase (original magnification × 400). (E) Immunohistochemical
staining for Ki-67 (original magnification × 400).
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systems, preoperative diagnosis was difficult. Only six
patients were diagnosed as or suspected of SPTs in our
series, and the misdiagnosis rate in other groups was
reported as ranging from 38.5% to more than 70%
[10,11]. According to our experience, data from CT or
MRI scans combined with age and sex should be suffi-
cient for the decision to operate, and FNAC should
be performed where the radiological diagnosis is not
clear enough.
Currently, complete aggressive surgical resection is
the treatment of choice for SPTs, even in the case of
local invasion or metastasis [12]. The surgical approach
depends on the location, size, and nature of theneoplasms, as well as the time of surgery [10]. Intra-
operative frozen section may be helpful to ascertain the
adequate of the resection margins. Extensive lymphatic
dissection is not warranted, as SPTs rarely have lymph
node metastases. For the case of local invasion or me-
tastases, there is also a consensus that surgical therapy
should be performed [13]. Because of the excellent out-
comes after complete resection [14], surgeons should
always aim for complete en-bloc resection including ad-
jacent structures preferably with microscopically clear
margins. In our study, the infiltrated splenic vein and
adjacent tissues were resected en bloc and a long-term
survival was observed in these patients. Resection of
distant metastases should be performed at the time of








Mean age (years) 34.4(19-55) 25.3(11-53) 0.11
Symptoms
Present 3 11 0.65
Absent 1 2
Tumor location




< 5 1 5 0.55
> 5 3 7
Tumor markers
Increased 1 1 0.35
Normal 3 12
Calcification
Present 1 3 0.94
Absent 3 10
Hemorrhage or necrosis
Present 2 4 0.48
Absent 2 9
Tumor feature
Solid and cystic 1 9 0.11
Solid 3 4
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sive approach is supported in some studies, which
showed that most patients were alive at long-term fol-
low-up after extended resection [12,15].
In our study, four patients with splenic vein infiltra-
tion or pancreatic parenchyma invasion were diag-
nosed as malignant SPTs. Some studies have shown a
correlation between tumor size above 5 cm, tumor ne-
crosis, the male sex, and SPTs with malignant poten-
tial [16,17]. However, several univariate analyses
indicated that clinical factors, including sex, age,
tumor size, tumor location, increased tumor markers,
and tumor characteristics were not intensively related
to the malignant potential of SPTs [4,10,18]. These
results were consistent with that in our study. More-
over, we found that positive immunoreactivity for Ki-67
was detected in three patients with pancreatic paren-
chyma invasion. Our findings are similar to the report
from Yang [10] and indicate that the detection of Ki-67
may correlate with the malignancy and poor outcome
of SPTs. However, these results are only limited toa small sample of SPTs, and more cases should be
detected for Ki-67 and other new biomarkers in further
studies.
Solid pseudopapillary tumors are readily diagnosable,
based on their pathological and immunohistochemical
features. The tumors contain a mixture of solid, cystic,
and pseudopapillary patterns in various proportions.
The solid portions of the tumor are composed of
uniform and polygonal epithelioid cells with well-
vascularized stroma and a discohesive arrangement
[14]. Immunohistochemically, SPTs are typically posi-
tive for vimentin, α1-antitrypsin, α1-antichymotrypsin,
and neuron-specific enolase [19], but the unique immu-
nohistochemical features with expression of CD56 and
CD10 were not consistent in recent studies. Cells from
SPTs may also reveal focal immunoreactivity for cyto-
keratin and synaptophysin, demonstrate abnormal nu-
clear localization of β-catenin and the presence of
progesterone receptors and may express galectin-3, all
of which are useful in differentiating SPTs from endo-
crine pancreatic tumors [20].
The prognosis of SPTs is good, even with local recur-
rence, as well as metastases or invasions. More than
95% of patients with SPTs limited to the pancreas are
cured by complete surgical excision [20]. Local recur-
rence is reported to be less than 10%, and usually
within 4 years of surgery [11]. Recurrence, local inva-
sion, and limited metastases are not contraindications
for resection, and long-term survival has also been
observed in patients with malignant SPTs. The overall
5-year survival was estimated to be 95% in a review of
718 patients reported in the English literature [21].
Owing to the favorable prognosis and excellent long-
term survival, even in the presence of local recurrence
or stable metastases, predictive factors of survival are
difficult to identify.Conclusions
Solid pseudopapillary tumors are infrequent, typically
affecting young women without notable symptoms.
Their behavior is relatively indolent and largely be-
nign, however, surgical resection is warranted even in
the presence of local invasion or metastases as
patients demonstrate excellent long-term survival.
Further studies should aim at acquiring more under-
standing of SPTs and establishing guidelines for SPT
diagnosis and treatment.Consent
Written informed consent was obtained from the pa-
tient for publication of this report and any accompany-
ing images.
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